Published in Am J Hematol on January 01, 2006
Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review. Haematologica (2009) 1.05
Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study. Haematologica (2009) 0.87
First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia. PLoS One (2011) 0.87
Stem cell transplantation of matched sibling donors compared with immunosuppressive therapy for acquired severe aplastic anaemia: a Cochrane systematic review. BMJ Open (2014) 0.81
Drug-Induced Neutropenia: A Focus on Rituximab-Induced Late-Onset Neutropenia. P T (2016) 0.75
Agranulocytosis - Sequelae of Chronic Cocaine Use: Case Series and Literature Review. Cureus (2017) 0.75
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med (2010) 10.64
Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA (2002) 10.03
Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med (2005) 7.09
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Telomere diseases. N Engl J Med (2009) 5.68
Hematopoietic-specific microRNA expression in human cells. Leuk Res (2005) 3.95
Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med (2012) 3.93
Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome. JAMA (2003) 3.90
Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med (2011) 3.82
Somatic Mutations and Clonal Hematopoiesis in Aplastic Anemia. N Engl J Med (2015) 3.42
Hybrid DNA virus in Chinese patients with seronegative hepatitis discovered by deep sequencing. Proc Natl Acad Sci U S A (2013) 3.35
Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.76
Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet (2003) 2.76
Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood (2003) 2.73
Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia. Blood (2006) 2.69
[First spontaneous reports of adverse reactions to the new selective COX-2 non-steroidal anti-inflammatory drugs]. Med Clin (Barc) (2002) 2.66
Prevalence and characteristics of opioid use in the US adult population. Pain (2008) 2.49
In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. Lancet (2004) 2.47
How I treat acquired aplastic anemia. Blood (2012) 2.44
Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A (2009) 2.44
Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood (2007) 2.36
Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica (2008) 2.15
Statin use and the risk of breast and prostate cancer. Epidemiology (2002) 2.15
Sex hormones, acting on the TERT gene, increase telomerase activity in human primary hematopoietic cells. Blood (2009) 2.12
Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood (2002) 2.10
Telomere maintenance and human bone marrow failure. Blood (2008) 2.09
Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets. J Fam Plann Reprod Health Care (2011) 2.07
Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. Blood (2013) 1.97
Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood (2008) 1.95
Th17 immune responses contribute to the pathophysiology of aplastic anemia. Blood (2010) 1.91
Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol (2006) 1.88
Treatment of severe aplastic anaemia with combined immunosuppression: anti-thymocyte globulin, ciclosporin and mycophenolate mofetil. Br J Haematol (2006) 1.82
Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol (2008) 1.82
Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol (2010) 1.79
Constitutional telomerase mutations are genetic risk factors for cirrhosis. Hepatology (2011) 1.77
Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study. Haematologica (2009) 1.73
Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities. Blood (2004) 1.70
Retreatment with rabbit anti-thymocyte globulin and ciclosporin for patients with relapsed or refractory severe aplastic anaemia. Br J Haematol (2006) 1.68
Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res (2012) 1.65
T-bet, a Th1 transcription factor, is up-regulated in T cells from patients with aplastic anemia. Blood (2006) 1.64
Mutations in the SBDS gene in acquired aplastic anemia. Blood (2007) 1.62
Functional characterization of natural telomerase mutations found in patients with hematologic disorders. Blood (2006) 1.57
A spectrum of severe familial liver disorders associate with telomerase mutations. PLoS One (2009) 1.57
HIV and pre-neoplastic and neoplastic lesions of the cervix in South Africa: a case-control study. BMC Cancer (2006) 1.54
Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis. Pediatrics (2009) 1.53
The Million Women Study: potential biases do not allow uncritical acceptance of the data. Climacteric (2004) 1.50
Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia. Br J Haematol (2008) 1.49
Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol (2002) 1.49
Analysis of T-cell repertoire in hepatitis-associated aplastic anemia. Blood (2004) 1.46
Deficient CD4+ CD25+ FOXP3+ T regulatory cells in acquired aplastic anemia. Blood (2007) 1.44
A mouse model of lymphocyte infusion-induced bone marrow failure. Exp Hematol (2004) 1.42
Medication use among children <12 years of age in the United States: results from the Slone Survey. Pediatrics (2009) 1.41
Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice. Exp Hematol (2008) 1.41
Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients. Exp Hematol (2004) 1.40
Ex vivo-generated CD36+ erythroid progenitors are highly permissive to human parvovirus B19 replication. J Virol (2007) 1.40
[Generic drug prescription at discharge from a hospital emergency service]. Med Clin (Barc) (2003) 1.39
Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program (2002) 1.39
The epidemiology of aplastic anemia in Thailand. Blood (2005) 1.38
Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor. Proc Natl Acad Sci U S A (2006) 1.36
Cough and cold medication use by US children, 1999-2006: results from the slone survey. Pediatrics (2008) 1.36
Functional characterization of telomerase RNA variants found in patients with hematologic disorders. Blood (2004) 1.33
Interferon-gamma-induced gene expression in CD34 cells: identification of pathologic cytokine-specific signature profiles. Blood (2005) 1.30
Minor antigen h60-mediated aplastic anemia is ameliorated by immunosuppression and the infusion of regulatory T cells. J Immunol (2007) 1.28
Reporting randomised clinical trials of analgesics after traumatic or orthopaedic surgery is inadequate: a systematic review. BMC Clin Pharmacol (2010) 1.27
Hematopoiesis in 3 dimensions: human and murine bone marrow architecture visualized by confocal microscopy. Blood (2010) 1.27
Cytokine signature profiles in acquired aplastic anemia and myelodysplastic syndromes. Haematologica (2010) 1.25
Infections in patients with aplastic anemia. Semin Hematol (2009) 1.25
Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med (2002) 1.25
Long-term outcome of pediatric patients with severe aplastic anemia treated with antithymocyte globulin and cyclosporine. J Pediatr (2008) 1.22
Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer (2009) 1.22
Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. Haematologica (2009) 1.20
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood (2002) 1.19
Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis (2003) 1.18
Nonisotopic detection of microRNA using digoxigenin labeled RNA probes. Mol Cell Probes (2006) 1.18
Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades. Clin Infect Dis (2011) 1.16
Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. Exp Hematol (2008) 1.15
Telomere length is inherited with resetting of the telomere set-point. Proc Natl Acad Sci U S A (2010) 1.15
Prevalence and correlates of exceeding the labeled maximum dose of acetaminophen among adults in a U.S.-based internet survey. Pharmacoepidemiol Drug Saf (2012) 1.14
Human parvovirus B19 causes cell cycle arrest of human erythroid progenitors via deregulation of the E2F family of transcription factors. J Clin Invest (2010) 1.14
Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs. J Clin Invest (2013) 1.13
Prevalence of parvovirus B19 in liver tissue: no association with fulminant hepatitis or hepatitis-associated aplastic anemia. J Infect Dis (2003) 1.13
Population-based drug-induced agranulocytosis. Arch Intern Med (2005) 1.13
Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure. Blood (2004) 1.12
In vitro and in vivo evidence of PNH cell sensitivity to immune attack after nonmyeloablative allogeneic hematopoietic cell transplantation. Blood (2003) 1.12
Marked mitochondrial DNA sequence heterogeneity in single CD34+ cell clones from normal adult bone marrow. Blood (2003) 1.10
T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood (2010) 1.09
Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine. Haematologica (2010) 1.09
Elevated circulating endothelial membrane microparticles in paroxysmal nocturnal haemoglobinuria. Br J Haematol (2004) 1.09
Risk of invasive cancer of the cervix in relation to the use of injectable progestogen contraceptives and combined estrogen/progestogen oral contraceptives (South Africa). Cancer Causes Control (2003) 1.08
Perforin gene mutations in patients with acquired aplastic anemia. Blood (2007) 1.07
Gene expression profiling in CD34 cells to identify differences between aplastic anemia patients and healthy volunteers. Blood (2003) 1.06
Safety and immunogenicity of a recombinant parvovirus B19 vaccine formulated with MF59C.1. J Infect Dis (2003) 1.05
Therapeutic ineffectiveness: heads or tails? Drug Saf (2002) 1.05